Candel Therapeutics, Inc. (CADL)

7.05 +0.64 (+9.98%) At close: 04:00PM EDT

Candel Therapeutics, Inc.

117 Kendrick Street
Suite 450
Needham, MA 02494
United States
617 916 5445
https://www.candeltx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 42

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.	President, CEO & Director	1.12M	N/A	1961
Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D.	Founder & Director	35k	N/A	1959
Dr. Francesca Barone M.D., Ph.D.	Chief Scientific Officer	506.76k	N/A	1978
Mr. Charles Schoch	Interim CFO, VP of Finance & Corporate Controller	N/A	N/A	1985
Dr. Seshu Tyagarajan Ph.D.	Chief Technical & Development Officer	335.27k	N/A	1968
Ms. Ileen B. Winick	Chief People Officer	N/A	N/A	N/A
Ms. Susan Stewart J.D., L.L.M.	Chief Regulatory Officer	N/A	N/A	1961
Dr. William Garrett Nichols M.D., M.S.	Chief Medical Officer	N/A	N/A	1969

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Corporate Governance

Candel Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.